Literature DB >> 4419005

Steady-state plasma concentrations of alprenolol in man.

M D Rawlins, P Collste, M Frisk-Holmberg, M Lind, J Ostman, F Sjöqvist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4419005     DOI： 10.1007/BF00558205

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  14 in total

1.  Phenylbutazone therapy; relation between the toxic and therapeutic effects and the blood level.

Authors:  E BRUCK; M E FEARNLEY; I MEANOCK; H PATLEY
Journal:  Lancet       Date:  1954-01-30       Impact factor: 79.321

2.  Double-blind three-dose trial of oral alprenolol in angina pectoris.

Authors:  E Sowton; C Smithen
Journal:  Br Heart J       Date:  1971-07

3.  Antihypertensive therapy with alprenolol, a beta-adrenergic receptor antagonist.

Authors:  G Tibblin; B Ablad
Journal:  Acta Med Scand       Date:  1969-11

4.  Use of alprenolol in acute cardiac arrhythmias.

Authors:  L Lemberg; A G Arcebal; A Castellanos; D Slavin
Journal:  Am J Cardiol       Date:  1972-07-11       Impact factor: 2.778

5.  Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man.

Authors:  B Ablad; K O Borg; G Johnsson; C G Regårdh; L Sölvell
Journal:  Life Sci       Date:  1974-02-16       Impact factor: 5.037

6.  Comparison of two adrenergic beta-receptor blocking agents, alprenolol and propranolol, in treatment of angina pectoris.

Authors:  D J Heterington; M B Comerford; G Nyberg; E M Besterman
Journal:  Br Heart J       Date:  1973-03

7.  Gas chromatographic determination of the secondary amine alprenolol, as its trifluoroacetyl derivative, at nanogram levels in biological fluids.

Authors:  M Ervik
Journal:  Acta Pharm Suec       Date:  1969-06

8.  Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man.

Authors:  L Lund; P K Lunde; A Rane; O Borga; F Sjöqvist
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

9.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

10.  Potency and time effect relationship in man of propranolol and H 56-28. I. Comparative studies after intravenous administration. II. Studies on the ratio of equipotent oral and intravenous doses.

Authors:  G Johnsson; A Norrby; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1967
View more
  11 in total

1.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

2.  Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Authors:  G Alván; M Lind; B Mellström; C von Bahr
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

Review 3.  Individual differences in the disposition of drugs metabolised in the body.

Authors:  G Alvan
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

4.  Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.

Authors:  G L Sanders; P A Routledge; A Ward; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

5.  Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.

Authors:  G L Sanders; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

6.  Single and multiple dose pharmacokinetics of pindolol.

Authors:  R Gugler; G Bodem
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Pharmacokinetics and pharmacodynamics of warfarin at steady state.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

9.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M L Orme; M D Rawlins; J Ostman
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

10.  Pharmacokinetics of tolamolol in the treatment of hypertension.

Authors:  P A Routledge; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.